AgingResearch.NewsJoin free

Retension Pharmaceuticals

CompanyUnited StatesFounded 2023

Retension Pharmaceuticals develops one asset, in phase 2 (RTN-001 in uncontrolled hypertension). Mostly small molecule; based in the United States, founded in 2023.

1
Asset
Furthest
Phase 2
1
Trial
0
Signals

Pipeline

1

  • RTN-001

    Modified release formulation for uncontrolled hypertension.

    Phase 2, Small molecule, uncontrolled hypertension

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Similar companies2

Updated 9 Oct 2026 · 4 sources

Intelligence